Avatrombopag maleate is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Avatrombopag Maleate was developed by Astellas Pharma.
The API has now reached off-patent status, after being launched in 2018.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Avatrombopag Maleate and many others, contact info@pharmacheminvestor.com